Concepts (86)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Motorcycles | 1 | 2011 | 8 | 0.410 |
Why?
|
| Automobile Driving | 1 | 2011 | 29 | 0.400 |
Why?
|
| Accidents, Traffic | 1 | 2011 | 116 | 0.380 |
Why?
|
| Wounds and Injuries | 1 | 2011 | 399 | 0.300 |
Why?
|
| Virus Diseases | 1 | 2011 | 398 | 0.300 |
Why?
|
| Cross Infection | 1 | 2011 | 544 | 0.280 |
Why?
|
| Critical Illness | 1 | 2011 | 714 | 0.270 |
Why?
|
| Mastectomy | 2 | 2020 | 1534 | 0.220 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2015 | 176 | 0.210 |
Why?
|
| Hospitalization | 1 | 2011 | 2083 | 0.210 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2018 | 1216 | 0.190 |
Why?
|
| Clostridium Infections | 2 | 2015 | 252 | 0.190 |
Why?
|
| Breast Neoplasms | 5 | 2021 | 15694 | 0.160 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 289 | 0.150 |
Why?
|
| Health Care Costs | 1 | 2020 | 674 | 0.130 |
Why?
|
| Image-Guided Biopsy | 1 | 2018 | 327 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 915 | 0.130 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 610 | 0.120 |
Why?
|
| Mastectomy, Segmental | 1 | 2019 | 1026 | 0.120 |
Why?
|
| Wound Infection | 1 | 2013 | 54 | 0.110 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 674 | 0.110 |
Why?
|
| Florida | 1 | 2011 | 113 | 0.100 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 1215 | 0.100 |
Why?
|
| Trauma Severity Indices | 1 | 2011 | 98 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1303 | 0.100 |
Why?
|
| Risk Factors | 5 | 2019 | 17523 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 1371 | 0.090 |
Why?
|
| Multiple Organ Failure | 1 | 2011 | 177 | 0.090 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 1959 | 0.090 |
Why?
|
| Shock, Septic | 1 | 2011 | 181 | 0.090 |
Why?
|
| Carcinoma | 1 | 2020 | 2578 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 13658 | 0.080 |
Why?
|
| Receptor, ErbB-2 | 1 | 2017 | 2518 | 0.080 |
Why?
|
| Diarrhea | 1 | 2011 | 686 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 2011 | 479 | 0.070 |
Why?
|
| Quality of Life | 1 | 2020 | 4532 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2017 | 2967 | 0.070 |
Why?
|
| Intensive Care Units | 1 | 2011 | 717 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2011 | 1274 | 0.070 |
Why?
|
| Adult | 7 | 2020 | 77950 | 0.060 |
Why?
|
| Axilla | 2 | 2018 | 902 | 0.060 |
Why?
|
| Comorbidity | 1 | 2011 | 2352 | 0.060 |
Why?
|
| Gene Expression | 1 | 2013 | 3570 | 0.060 |
Why?
|
| Influenza, Human | 1 | 2011 | 925 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2020 | 37905 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2017 | 6869 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 29902 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 3 | 2021 | 4975 | 0.050 |
Why?
|
| Aged | 6 | 2020 | 70117 | 0.050 |
Why?
|
| Incidence | 1 | 2011 | 5673 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 14889 | 0.050 |
Why?
|
| Middle Aged | 6 | 2020 | 86204 | 0.050 |
Why?
|
| Young Adult | 3 | 2017 | 21445 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 3890 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2019 | 12873 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2020 | 430 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 5539 | 0.040 |
Why?
|
| Prognosis | 2 | 2019 | 21713 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2011 | 9244 | 0.040 |
Why?
|
| Female | 7 | 2021 | 141928 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 14289 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 4844 | 0.040 |
Why?
|
| Survival Rate | 1 | 2011 | 12221 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 1085 | 0.040 |
Why?
|
| Humans | 9 | 2021 | 261506 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 799 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2017 | 690 | 0.030 |
Why?
|
| United States | 1 | 2011 | 15433 | 0.030 |
Why?
|
| Male | 3 | 2015 | 123000 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 2292 | 0.030 |
Why?
|
| Mammography | 1 | 2018 | 1010 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 4314 | 0.020 |
Why?
|
| Leukocytes | 1 | 2013 | 422 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2017 | 1863 | 0.020 |
Why?
|
| Texas | 1 | 2020 | 6311 | 0.020 |
Why?
|
| Patient Selection | 1 | 2017 | 2055 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 10001 | 0.020 |
Why?
|
| Brain Injuries | 1 | 2015 | 787 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 6009 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 3719 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 2508 | 0.020 |
Why?
|
| Inflammation | 1 | 2015 | 2522 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4320 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 4109 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 10035 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 31252 | 0.010 |
Why?
|